(Bloomberg) -- Martin Shkreli, the pharmaceutical CEO arrested on securities fraudcharges this week, may have made drug price increasesnotorious in the U.S.

But his strategy of finding an old drug, raising its price, andtaking the profit is one that’s increasingly common among anew breed of drugmakers.

Disdaining a business model dependent on expensive research anddevelopment, companies like Shkreli’s Turing Pharmaceuticals AG,Valeant Pharmaceuticals International Inc., Rodelis Therapeutics,and others have taken advantage of inefficiencies in the U.S.health-care system.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care